---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-028373"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:02:30.455103+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Intellia Q4 net loss $128.9M; cuts workforce 27%, ends NTLA-3001

## Summary
- Q4 2024 net loss $128.9M vs $132.2M prior year; revenue $12.9M.
- Ended 2024 with $861.7M cash; funding into first half of 2027.
- Workforce reduction of ~27% in 2025; expects $8M severance charges.
- Phase 3 HAELO (NTLA-2002) dosed first patient; BLA submission planned H2 2026.
- Enrollment in MAGNITUDE (nex-z for ATTR-CM) ahead of projections, >550 patients by year end.

## SEC filing metadata
- accession: 0000950170-25-028373
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000095017025028373/0000950170-25-028373-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000095017025028373/ntla-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-028373
- JSON: https://secwatch.observer/filing/0000950170-25-028373.json
- Plain text: https://secwatch.observer/filing/0000950170-25-028373.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.